lorlatinib

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
Thu, 03/15/18 - 09:55 am
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA
Endpoints
Mon, 10/16/17 - 12:00 pm
Pfizer
lorlatinib
FDA
non-small cell lung cancer
Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII
Endpoints
Thu, 04/27/17 - 05:49 pm
Pfizer
breakthrough status
lorlatinib
metastatic non-small cell lung cancer